RAPYD
22.9.2022 09:57:36 CEST | Business Wire | Press release
Nearly seven out of 10 (67%) Europeans demand direct bank transfers as their most preferred method to be paid, indicating the growing need for businesses to provide fast and secure payments in consumers’ preferred payout methods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005160/en/
Source: Rapyd’s 2022 European eCommerce and Payment Methods report (Graphic: Business Wire)
That’s according to a new report released by Rapyd, the leading fintech-as-a-service partner, after conducting research to understand consumer choices, considerations and preferences in nine European countries; including data on how consumers prefer to pay and receive payments.
Rapyd’s European State of Disbursements report finds that access to, and interest in, financial technology apps is very high among consumers in the nine European markets surveyed. Europeans are embracing financial services apps for everything from banking, everyday spending and managing their investments. The findings show that 74% of European consumers use a mobile banking app, 50% use an eWallet app, 50% use a credit or debit card app, approximately one in six (16%) use an investment fund app and approximately one in eight (12%) use a personal financial management app.
Rapyd’s European eCommerce and Payment Methods report also indicates that Europeans increasingly rely on phones for payments, financial management and eCommerce. Over half (52%) of Europeans report purchasing clothes online via mobile over the past three months, compared to 46% via laptop. Furthermore, the overwhelming majority of Europeans who purchased takeaway over the last 3 months did so via mobile (70%) compared to laptop (28%).
Rapyd’s State of Disbursements report also noted that Europeans are early adopters of fintech, prioritizing data security and lower costs when receiving payments. Only 16% are hesitant or lagging in the adoption of fintech. The data shows that 82% rank keeping their personal information secure as the most important feature for payouts, and over 70% of respondents do not want to pay any transaction fees.
The report further analyzes and compares each market’s attitudes towards fintech adoption. Interestingly, Spain had the highest number of early adopters or consumers more likely to be open to new fintech solutions (27%), followed by Iceland (22%) and Germany (20%). On the other hand, Denmark (54%), France (47%) and the UK (44%) had the highest number of consumers who identified as the ‘late majority.’ The analysis notes that these consumers are less likely to explore new financial technology, instead preferring to use the same platforms as family and friends.
Over half of global online transfers are currently made with local or alternative payment methods. This, coupled with the rapid growth of marketplaces and gig economy models, is driving the need for new payout technology in Europe, notes the report.
Rapyd also notes that with the roll-out of the Single Euro Payments Area (SEPA) continuing and the Nordics’ P27 payments initiative unfolding, real-time payments in Europe are here to stay, emphasizing the need to keep abreast of country-specific regulations. As such, the company is calling on businesses to ensure they have the infrastructure in place to guarantee reliable mass payouts driven by local preferences.
Commenting on the findings, Arik Shtilman, CEO of Rapyd, said:
“The companies that solve the technological challenges of disbursing funds in Europe will surge ahead of their competition. It’s critical that businesses responsible for online financial transactions have partners that can support them in delivering reliable payout and payment solutions, can keep on top of local regulations and can stay on top of consumer preferences. The businesses that invest in dynamic tech solutions to guarantee reliable mass payouts will no doubt enjoy stability and growth through better engagement, loyalty and beneficiary preference.
“Furthermore, given the growth of marketplaces and gig-economy platforms, working with partners that understand the evolving fintech space is key. Disbursing funds to a seller or worker is typically tied to individual sales on different platforms. This can be incredibly complex, as in many cases, the buyer, seller and platform provider are all in different locations. We recommend that businesses ensure local preferences are driving their payout strategy, with a particular focus on speed, security and choice, as these factors help drive greater use and adoption and build loyalty and trust.”
Rapyd’s 2022 European eCommerce and Payment Methods report and 2022 European State of Disbursements report are available here.
Notes to Editors:
Survey Methodology
Rapyd surveyed 4,286 adults (18+) in Denmark, France, Germany, Iceland, Italy, Netherlands, Sweden, Spain and the United Kingdom online in March and April 2022. All respondents made an online purchase in the previous month and were nationally representative across age and income scale.
About Rapyd
Rapyd lets you build bold. Liberate global commerce with all the tools your business needs to create payment, payout and fintech experiences everywhere. From Fortune 500s to ambitious business and technology upstarts, our payments network and powerful fintech platform make it easy to pay suppliers and get paid by customers—locally or internationally.
With offices worldwide, including Tel Aviv, Dubai, London, Iceland, San Francisco, Miami and Singapore, we know what it takes to make cross-border commerce as easy as being next door. Rapyd simplifies payments so you can focus on building your business.
Get the tools to grow globally at www.rapyd.net. Follow: Blog, Insta, LinkedIn, Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
